Unspecified low-molecular-weight-heparins/warfarin
- PDF / 169,384 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 3 Downloads / 231 Views
1 S
Haemorrhagic cerebrovascular events: case report In a multicenter retrospective study (ANATOLIA-PREG Registry) of 110 female patients, one female patient [age not stated] was described, who developed haemorrhagic cerebrovascular events following anticoagulation therapy with warfarin and unspecified low molecular weight heparin during pregnancy. The pregnant woman, who had undergone mechanical prosthetic heart valve placement, started receiving anticoagulant therapy with unspecified low molecular weight heparin in the first trimester of her pregnancy, followed by warfarin in her second and third trimester of the pregnancy [routes and dosages not stated]. Subsequently, she developed haemorrhagic cerebrovascular events [duration of treatment to reaction onset not stated]. She also had obstructive prosthetic valve thrombosis. Thereafter, she died of cardiogenic shock. Guner A, et al. Comparison of Different Anticoagulation Regimens Regarding Maternal and Fetal Outcomes in Pregnant Patients With Mechanical Prosthetic Heart Valves (from the Multicenter ANATOLIA-PREG Registry). American Journal of Cardiology 127: 113-119, 15 Jul 2020. Available from: URL: http://doi.org/10.1016/ 803502185 j.amjcard.2020.04.010
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
